Stockscreener 앱 받기
2.19
18.70%
-0.51
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 data - Endpoints News
Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial - GuruFocus
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Ey - GuruFocus
Breakthrough in Dry Eye Treatment: Aldeyra's Reproxalap Achieves Significant Phase 3 Results, FDA Filing Next - Stock Titan
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap - Business Wire
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
Invesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) - GlobeNewswire
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Renaissance Technologies LLC Purchases 59,700 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics Inc (ALDX) Stock: Navigating a Year of Stock Volatility - investchronicle.com
It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock - Sete News
Neuropathic Ocular Pain Pipeline 2025: In-depth Clinical - openPR.com
Investing in Aldeyra Therapeutics Inc (ALDX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, In - GuruFocus
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
Aldeyra Therapeutics Inc (ALDX): Why Is Stock So Good? - Marketing Sentinel
Raymond James Financial Inc. Makes New $3.63 Million Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - American Banking and Market News
ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) - GlobeNewswire
Wells Fargo & Company MN Acquires 7,348 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Geode Capital Management LLC Grows Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALDX - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Open Lending Corp. - GlobeNewswire Inc.
Aldeyra Therapeutics Inc (ALDX) Stock: A Year of Declines and Increases - investchronicle.com
Volatility Of Aldeyra Therapeutics Inc (ALDX) Reaches 9.20%: Make Sure To Keep Your Seat Tight! - Stocksregister
ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money - TradingView
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire
LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - GlobeNewswire
Analytical Lens: Exploring Aldeyra Therapeutics Inc (ALDX)’s Financial Story Through Ratios - DWinneX
Aldeyra Therapeutics Inc (ALDX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Latest Insider moments: PERCEPTIVE ADVISORS LLC, Aldeyra Therapeutics Inc [ALDX] 10% Owner sold 3,400,000 shares – Knox Daily - knoxdaily.com
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha
ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit - GlobeNewswire
ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation - markets.businessinsider.com
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ALDX INVESTOR INVESTIGATION: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors - citybiz
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors | ALDX Stock News - GuruFocus
30-Year Biotech Leader Chip Clark Strengthens Aldeyra Board: Strategic Move for Pipeline Advancement - Stock Titan
Research Analysts Set Expectations for ALDX Q1 Earnings - Defense World
7.02%
자본화:
|
볼륨(24시간):